Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
haNK Cell Therapy and Vaccines in Advanced HCC
NCT03563170Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- May 2018
- Primary completion
- Aug 2019
- Modality
- Adenoviral Vectors, Fc-Fusion Proteins, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of haNK, nogapendekin alfa inbakicept, ETBX-011, ETBX-051, ETBX-061 in hepatocellular carcinoma (HCC), sponsored by ImmunityBio, Inc.. Planned start May 2018; status: withdrawn.
02
Drugs
haNKnogapendekin alfa inbakiceptETBX-011ETBX-051ETBX-061
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03563170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563170.